Overview

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Status:
Recruiting
Trial end date:
2021-03-15
Target enrollment:
Participant gender:
Summary
Open-label, Phase 2, single treatment arm, 3 cohorts
Phase:
Phase 2
Details
Lead Sponsor:
Rain Therapeutics Inc.
Treatments:
Bromides